A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.
Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.